Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.2680
+0.0007 (+0.26%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
August 15, 2023
From
Cybin Inc.
Via
Business Wire
Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic
August 14, 2023
Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023:
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2024 Financial Results, Business Highlights
August 14, 2023
Via
Investor Brand Network
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
Cybin Reports First Quarter Financial Results and Recent Business Highlights
August 14, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M
August 04, 2023
Psychedelics biotech Cybin Inc. (NYSE: CYBN) closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Closing of Marketed Public Offering
August 04, 2023
Via
Investor Brand Network
Cybin Announces Closing of Overnight Marketed Public Offering of Units
August 04, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort
August 02, 2023
Via
Investor Brand Network
Exposures
Product Safety
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
August 02, 2023
From
Cybin Inc.
Via
Business Wire
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 01, 2023
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list.
Via
Benzinga
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal
August 01, 2023
Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Overnight Public Offering
August 01, 2023
Via
Investor Brand Network
US Stocks Mixed; Pfizer Earnings Beat Views
August 01, 2023
U.S. stocks were mixed this morning, with the Dow Jones trading slightly higher on Tuesday. Following the market opening Tuesday, the Dow traded up 0.03% to 35,568.68 while the NASDAQ fell 0.57% to...
Via
Benzinga
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
August 01, 2023
From
Cybin Inc.
Via
Business Wire
Why TETRA Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
August 01, 2023
Gainers American Superconductor Corporation (NASDAQ: AMSC) shares surged 112.1% to $21.38 in pre-market trading. AMSC is expected to report first-quarter results on Aug. 9, 2023.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 01, 2023
It's time for a look at the biggest pre-market stock movers as we check out the latest news worth reading on Tuesday morning!
Via
InvestorPlace
Cybin Announces Overnight Marketed Public Offering of Units
July 31, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plans to Participate in Annual Canaccord Genuity Growth Conference
July 27, 2023
Via
Investor Brand Network
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 27, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Global CRO Partner to Study, Develop CYB003 as Effective MDD Treatment
July 26, 2023
Via
Investor Brand Network
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
July 26, 2023
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END
Via
FinancialNewsMedia
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
July 26, 2023
From
Cybin Inc.
Via
Business Wire
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
July 24, 2023
Cybin One Steps Away From Complete Dosing
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Significant Milestone in Advancing CYB003 Towards Pivotal Studies
July 24, 2023
Via
Investor Brand Network
Exposures
Product Safety
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
July 24, 2023
From
Cybin Inc.
Via
Business Wire
A Quantum Leap In Psychedelic Research: Study Shows Real-Time Brain Changes After Ketamine Use
July 21, 2023
A newly published study shows that Kernel’s Flow technology system is in fact able to capture and analyze brain changes following the administration of a psychoactive substance.
Via
Benzinga
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
July 20, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
July 20, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.